Galderma Group AG Logo

Galderma Group AG

A pure-play dermatology company with aesthetics, skincare, and therapeutic solutions.

GALD | SW

Overview

Corporate Details

ISIN(s):
CH1335392721
LEI:
89450001OK6O8ELQ4584
Country:
Switzerland
Address:
Zählerweg 10, 6300 Zug
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Galderma Group AG is a pure-play pharmaceutical company specializing in dermatology. It operates across the full spectrum of skin health through three main business units: Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology. The company develops and markets an innovative, science-based portfolio of premium brands and treatments designed to meet the individual needs of both consumers and patients. Galderma is focused on providing solutions for a wide range of dermatological conditions, positioning itself as a leader solely dedicated to advancing skin health.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Galderma Group AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Galderma Group AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-31 N/A Non-Executive member Sell None 935,664.75 CHF
2025-03-28 N/A Non-Executive member Sell None 1,876,958.07 CHF
2025-03-27 N/A Non-Executive member Sell None 265,440.84 CHF
2025-03-26 N/A Non-Executive member Sell None 673,175.70 CHF
2025-03-25 N/A Executive member Buy None 243,205.38 CHF
2025-03-20 N/A Non-Executive member Sell None 1,156,106.24 CHF
2025-03-20 N/A Non-Executive member Sell None 47,702.12 CHF
2025-03-17 N/A Executive member Sell None 7,962,599.99 CHF
2024-12-20 N/A Non-Executive member Sell None 105,831.00 CHF
2024-11-06 N/A Non-Executive member Sell None 177,500.00 CHF

Peer Companies

Company Country Ticker View
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan 4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom ANCR
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea 065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania ATB
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany APPH
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea 397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea 003060
Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea 007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea 293780

Talk to a Data Expert

Have a question? We'll get back to you promptly.